Participants in the 72-week STEP UP trial who received the increased Wegovy dose of 7.2 mg experienced a mean weight reduction of 21%, while a third of them reached 25% body weight loss. Adults with ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss effects that weren’t as strong as previously reported.

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...

This new pill works by triggering the metabolism in the muscles, activating them to burn more fat, without the ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

“ATR-258, a synthetic small molecule, has favourable pharmacokinetics and in Phase 1 clinical trials has been administered just once a day as a capsule, making it a straightforward, patient-friendly ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

A PILL to make you buff is a step nearer to reality as inventors move onto the next phase of human trials. Scientists say the ...